Osimertinib induced adverse cardiac events: a case report

Osimertinib is a third-generation epidermal growth factor receptor(EGFR)—tyrosine kinase inhibitors(TKI)selective for both EGFR-TKI sensitizing and T790M resistance mutations.It is also recommended as firstline therapy for patients with non-small-cell lung cancer(NSCLC)who have targetable EGFR mutations.[1]Recently,some emerging evidence revealed the significant cardiac toxicity induced by osimertinib.However,osimertinib-induced dilated cardiomyopathy and congestive heart failure has never been reported in China.Here,we report a rare case of dilated cardiomyopathy with heart failure exacerbation which developed during osimertinib treatment.